Name Meloxicam
Classes Analgesic / Pain Killer
Central Nervous System Agent
Diseases Arthritis
Inflammatory Disease


MELOXICAM is an oxicam-class nonsteroidal anti-inflammatory drug used to treat the symptoms of painful inflammatory disorders such as arthritis. MELOXICAM acts by inhibiting the formation of endogenous prostaglandins, which play a role in pain, stiffness, tenderness, and edema mitigation.

MELOXICAM is indicated:
• For relief of the signs and symptoms of osteoarthritis.
• For relief of the signs and symptoms of rheumatoid arthritis.

  • Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals 
  • For management of osteoarthritis pain, the recommended starting dosage is 5 mg orally once daily.
  • Dose may be increased to 10 mg in patients who require additional analgesia.
  • The maximum recommended daily oral dose of MELOXICAM is 10 mg.
  • In patients on hemodialysis, the maximum daily dosage is 5 mg

Commonly associated side effects include-

  • Edema
  • Anorexia
  • Abdominal pain
  • Constipation
  • Diarrhea
  • Dyspepsia
  • Liver problems
  • Anemia
  • Rash
  • Tinnitus
  • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk
  • MELOXICAM cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency.
  • The pharmacological activity of MELOXICAM in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
  • Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including MELOXICAM.
  • Because of reports of adverse eye findings with nonsteroidal anti-inflammatory agents, it is recommended that patients who develop visual complaints during treatment with MELOXICAM have ophthalmic evaluations.
  • Since cross-reactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, MELOXICAM should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
  • NSAIDs including MELOXICAM cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.


MELOXICAM is contraindicated in patients with known hypersensitivity to piroxicam or other oxicams, such as-

  • MELOXICAM should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.  Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients .
  • MELOXICAM is contraindicated for the treatment of peri-operative pain in the setting of coronary artery
    bypass graft (CABG) surgery.